Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
Sildenafil citrate
Known as:
1-((3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate
, Citrate, Sildenafil
, Sildenafil Citrate [Chemical/Ingredient]
The citrate salt of a pyrazolopyrimidinone derivative structurally related to zaprinast. Sildenafil selectively inhibits cyclic guanosine…
Expand
National Institutes of Health
Create Alert
Related topics
Related topics
34 relations
12.5 ML sildenafil 0.8 MG/ML Injection
Acetildenafil
Desmethyl Sildenafil
Drug Allergy
Expand
Narrower (5)
Homosildenafil
NCX-911
Revatio
UK 92480-10
Expand
Broader (4)
Phosphodiesterase 5 inhibitor
Urological Agents
Vasodilator Agents
sildenafil
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double…
K. McVary
,
William B. Monnig
,
Joseph L. Camps
,
J. M. Young
,
Li-Jung Tseng
,
Gene van den Ende
The Journal of urology
2007
Corpus ID: 29671514
PURPOSE We evaluated sildenafil for erectile dysfunction and lower urinary tract symptoms in men with the 2 conditions…
Expand
Highly Cited
2006
Highly Cited
2006
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
M. Pillinger
2006
Corpus ID: 57940593
Highly Cited
2005
Highly Cited
2005
Sildenafil citrate therapy for pulmonary arterial hypertension.
N. Galié
,
H. Ghofrani
,
+10 authors
G. Simonneau
The New England journal of medicine
2005
Corpus ID: 8614347
BACKGROUND Sildenafil inhibits phosphodiesterase type 5, an enzyme that metabolizes cyclic guanosine monophosphate, thereby…
Expand
Highly Cited
2002
Highly Cited
2002
Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder.
R. Basson
,
Rosemary McInnes
,
M. D. Smith
,
Gemma Hodgson
,
N. Koppiker
Journal of women's health & gender-based medicine
2002
Corpus ID: 9809359
OBJECTIVE Sildenafil citrate (Viagra Pfizer, New York, NY) is indicated for the treatment of erectile dysfunction in men. The…
Expand
Highly Cited
1999
Highly Cited
1999
Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group.
M. Rendell
,
J. Rajfer
,
P. Wicker
,
M. D. Smith
JAMA
1999
Corpus ID: 43662200
CONTEXT Erectile dysfunction is common in men with diabetes. OBJECTIVE To assess the efficacy and safety of oral sildenafil…
Expand
Review
1999
Review
1999
Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee.
M. Cheitlin
,
A. Hutter
,
+4 authors
R. Zusman
Circulation
1999
Corpus ID: 15096966
The pharmaceutical preparation sildenafil citrate (Viagra) is being widely prescribed as a treatment for male erectile…
Expand
Highly Cited
1999
Highly Cited
1999
Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist.
D. Webb
,
S. Freestone
,
M. J. Allen
,
G. Muirhead
The American journal of cardiology
1999
Corpus ID: 1755556
Sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), is a well…
Expand
Highly Cited
1999
Highly Cited
1999
Effects of sildenafil citrate on human hemodynamics.
G. Jackson
,
N. Benjamin
,
N. Jackson
,
M. J. Allen
The American journal of cardiology
1999
Corpus ID: 35258718
Nitric oxide (NO) induces the formation of intracellular cyclic guanosine monophosphate (cGMP) by guanylate cyclase. Sildenafil…
Expand
Review
1999
Review
1999
Overall cardiovascular profile of sildenafil citrate.
R. Zusman
,
A. Morales
,
D. Glasser
,
I. Osterloh
The American journal of cardiology
1999
Corpus ID: 23470103
Sildenafil, a selective inhibitor of phosphodiesterase type 5 (PDE5), is the first in a new class of orally effective treatments…
Expand
Highly Cited
1998
Highly Cited
1998
Clinical safety of oral sildenafil citrate (VIAGRATM) in the treatment of erectile dysfunction
A. Morales
,
C. Gingell
,
M. Collins
,
PA Wicker
,
I. Osterloh
International Journal of Impotence Research
1998
Corpus ID: 23628347
Sildenafil citrate has been shown to be effective in a wide range of patients with erectile dysfunction and has been approved in…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE